Evidence map›Paper›PMID 30777125›Full record

ArticleJournal for immunotherapy of cancer2019

NKG2D signaling certifies effector CD8 T cells for memory formation.

Cynthia Perez, Kushal Prajapati, Brianna Burke, Lourdes Plaza-Rojas, Nancy J Zeleznik-Le, Jose A Guevara-Patino

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Soluble NKG2D ligands impair CD8Oncology letters · 2023
    Article
  7. Review
  8. Article
  9. How Does Vitamin D Affect Immune Cells Crosstalk in Autoimmune Diseases?International journal of molecular sciences · 2023
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. The Role of the NKG2D in Vitiligo.Frontiers in immunology · 2021
    Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Cynthia PerezOncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL, USA.
Kushal PrajapatiOncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL, USA.
Brianna BurkeOncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL, USA.
Lourdes Plaza-RojasOncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL, USA.
Nancy J Zeleznik-LeOncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL, USA.
Jose A Guevara-PatinoOncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL, USA. jaguevara@luc.edu.

Funding

TCR TRANSDUCED CDB T CELLS FOR ADOPTIVE IMMUNOTHERAPYP01CA154778 · NCI · LOYOLA UNIVERSITY CHICAGO · PI NISHIMURA, MICHAEL I. · 2011 to 2015
$15.4M
NCI NIH HHS P01 CA154778NIH HHS RO1 CA188395
6 · The paper itself

Abstract

backgroundThe development of memory responses is an evolutionary function of the adaptive immune system. We propose that for the immune system to populate the memory compartment with the best-suited CD8 T cells it utilizes a process of certification or molecular accreditation mediated through Natural Killer Group 2D (NKG2D). This process of certification assures that the memory compartment is filled with CD8 T cells that have demonstrated their ability to kill their cognate targets through a two-step process that utilizes T cell receptor (TCR) and NKG2D signaling.

methodsOne week after immunization with peptide-pulsed dendritic cells, NKG2D signaling was transiently blocked in vivo with a single injection of neutralizing antibodies. Under such conditions, we determined the importance of NKG2D signaling during the effector phase for memory formation without compromising NKG2D signaling at the memory phase. Both open (polyclonal) and closed (monoclonal) CD8 T cell repertoires were studied.

resultsWe show that signaling through NKG2D mediated this certification. Temporary blockade of NKG2D signaling during the effector phase resulted in the formation of highly defective memory CD8 T cells characterized by altered expression of the ribosomal protein S6 and epigenetic modifiers, suggesting modifications in the T cell translational machinery and epigenetic programming. Finally, these uncertified memory cells were not protective against a B16 tumor challenge.

conclusionSignaling through NKG2D during the effector phase (certification) favors the development of functional memory CD8 T cells, a previously undescribed role for NKG2D. Temporary blockade of NKG2D signaling during the effector phase results in the formation of highly defective memory CD8 T cells potentially by affecting the expression of the ribosomal protein S6 and epigenetic modifiers, suggesting alterations in T cell translational machinery and epigenetic programming.

Indexed as

Immunologic MemoryAnimalsCD8-Positive T-LymphocytesMelanoma, ExperimentalMice, Inbred C57BLMice, TransgenicNK Cell Lectin-Like Receptor Subfamily KKlrk1 protein, mouseNK Cell Lectin-Like Receptor Subfamily KCD8 T cellsImmunological memoryMemory formationMouse modelsNKG2D

Identifiers

PMID30777125
PMCPMC6380053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.